Published in Lancet on July 21, 2011
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma | NCT00278525
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46
Report: Stem cell applications in neurological practice, an expert group consensus appraisal. Ann Indian Acad Neurol (2016) 1.37
Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest (2013) 1.24
Renal involvement in autoimmune connective tissue diseases. BMC Med (2013) 1.21
Scleroderma lung disease. Eur Respir Rev (2013) 1.04
Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol (2014) 0.94
Systemic sclerosis--challenges for clinical practice. Nat Rev Rheumatol (2012) 0.92
Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant (2013) 0.90
Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) (2014) 0.89
Interstitial lung disease in scleroderma. Rheum Dis Clin North Am (2015) 0.88
Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am (2015) 0.85
Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol (2014) 0.83
Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One (2015) 0.83
Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol (2015) 0.83
Targeted therapies for systemic sclerosis. Nat Rev Rheumatol (2013) 0.82
Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol (2017) 0.81
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant (2015) 0.81
My approach to the treatment of scleroderma. Mayo Clin Proc (2013) 0.81
Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol (2013) 0.81
Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther (2016) 0.79
Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice? JAMA (2014) 0.79
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients. Bone Marrow Transplant (2016) 0.78
Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int (2017) 0.78
Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs (2015) 0.77
Stem cells: HSCT for systemic sclerosis--swallows and summers. Nat Rev Rheumatol (2011) 0.77
Autologous HSCT in systemic sclerosis: a step forward. Lancet (2011) 0.77
Haemopoietic stem-cell transplantation for systemic sclerosis. Lancet (2012) 0.76
The role of the acquired immune response in systemic sclerosis. Semin Immunopathol (2015) 0.75
Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant (2016) 0.75
Stem cells in dermatology. An Bras Dermatol (2014) 0.75
Hematopoietic stem cell transplantation for auto immune rheumatic diseases. World J Transplant (2016) 0.75
Predictors of inpatient mortality in patients with systemic sclerosis: a case control study. Clin Rheumatol (2016) 0.75
Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. Arthritis Rheumatol (2016) 0.75
Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis. Rev Bras Hematol Hemoter (2013) 0.75
Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. J Hematol Oncol (2017) 0.75
Targeted Therapy in Systemic Sclerosis. Rambam Maimonides Med J (2016) 0.75
Cellular Therapies in Systemic Sclerosis: Recent Progress. Curr Rheumatol Rep (2016) 0.75
[Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems]. Z Rheumatol (2013) 0.75
[Pulmonary fibrosis in rheumatic diseases]. Z Rheumatol (2016) 0.75
[Autologous stem cell transplantation in systemic sclerosis]. Z Rheumatol (2016) 0.75
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol (2013) 5.09
Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA (2007) 4.59
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol (2007) 3.92
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A (2008) 3.39
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plast Reconstr Surg (2012) 3.30
Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology (2012) 3.29
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24
Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA (2008) 3.23
The United States rheumatology workforce: supply and demand, 2005-2025. Arthritis Rheum (2007) 3.23
Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow patterns, wall shear stress, and expression of aortopathy. Circulation (2013) 3.23
Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med (2007) 2.95
Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail (2011) 2.92
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc (2006) 2.89
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation (2010) 2.77
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J (2008) 2.71
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail (2008) 2.69
Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) (2005) 2.51
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med (2008) 2.42
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol (2006) 2.37
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA (2006) 2.34
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J (2004) 2.32
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA (2013) 2.17
Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol (2005) 2.16
Cardiac magnetic resonance imaging is more diagnostic than 2-dimensional echocardiography in determining the presence of bicuspid aortic valve. J Thorac Cardiovasc Surg (2011) 2.15
Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology (2010) 2.10
Risk stratification after hospitalization for decompensated heart failure. J Card Fail (2004) 2.04
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail (2015) 2.03
Clinical problem-solving. Anchors away. N Engl J Med (2007) 2.02
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J (2007) 2.01
Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation (2003) 1.99
Higher hemoglobin is associated with improved outcome after subarachnoid hemorrhage. Crit Care Med (2007) 1.97
Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail (2008) 1.97
A pilot study to assess benefit of atrial rhythm control after cardiac resynchronization therapy and atrioventricular node ablation. Pacing Clin Electrophysiol (2014) 1.97
Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke (2009) 1.96
The role of the emergency department in acute heart failure clinical trials--enriching patient identification and enrollment. Am Heart J (2013) 1.95
Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol (2011) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes (2011) 1.88
Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation (2010) 1.84
Quiescent-interval single-shot unenhanced magnetic resonance angiography of peripheral vascular disease: Technical considerations and clinical feasibility. Magn Reson Med (2010) 1.83
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol (2009) 1.80
Associations between outpatient heart failure process-of-care measures and mortality. Circulation (2011) 1.77
Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2013) 1.75
Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol (2008) 1.75
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood (2010) 1.74
Evidence-based use of levosimendan in different clinical settings. Eur Heart J (2006) 1.73
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. J Card Fail (2006) 1.72
3D noncontrast MR angiography of the distal lower extremities using flow-sensitive dephasing (FSD)-prepared balanced SSFP. Magn Reson Med (2009) 1.72
Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation (2011) 1.71
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation (2011) 1.71
The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J (2011) 1.66
Esophagogastric junction distensibility assessed with an endoscopic functional luminal imaging probe (EndoFLIP). Gastrointest Endosc (2010) 1.64
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol (2012) 1.64
Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol (2006) 1.64
Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthalmol (2004) 1.63
The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther (2008) 1.63
Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail (2008) 1.63
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
A propensity matched study of the association of education and outcomes in chronic heart failure. Int J Cardiol (2007) 1.62
The Valsalva maneuver: a bedside "biomarker" for heart failure. Am J Med (2006) 1.57
Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J (2012) 1.57
Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol (2009) 1.56
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol (2003) 1.56